412 related articles for article (PubMed ID: 25548993)
41. Deciphering Tumor Cell Evolution in Cutaneous T-Cell Lymphomas: Distinct Differentiation Trajectories in Mycosis Fungoides and Sézary Syndrome.
Jiang TT; Cao S; Kruglov O; Virmani A; Geskin LJ; Falo LD; Akilov OE
J Invest Dermatol; 2024 May; 144(5):1088-1098. PubMed ID: 38036289
[TBL] [Abstract][Full Text] [Related]
42. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
Collins K; Gu J; Aung PP; Nagarajan P; Curry JL; Huen A; Ivan D; Prieto VG; Tetzlaff MT; Duvic M; Miranda RN; Vega F; Torres-Cabala CA
Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
[TBL] [Abstract][Full Text] [Related]
43. CD30+ large cell transformation of mycosis fungoides after psoralen plus ultraviolet A photochemotherapy.
Ogino J; Saga K; Kagaya M; Kamada A; Hirosaki K; Kaneko R; Jimbow K
Br J Dermatol; 2007 Jan; 156(1):148-51. PubMed ID: 17199582
[TBL] [Abstract][Full Text] [Related]
44. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
[TBL] [Abstract][Full Text] [Related]
45. Alemtuzumab in Sézary syndrome: efficient but not innocent.
Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
[TBL] [Abstract][Full Text] [Related]
46. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab.
Kennedy GA; Seymour JF; Wolf M; Januszewicz H; Davison J; McCormack C; Ryan G; Prince HM
Eur J Haematol; 2003 Oct; 71(4):250-6. PubMed ID: 12950233
[TBL] [Abstract][Full Text] [Related]
47. CD4/CD8 double negative mycosis fungoides with PD-1 (CD279) expression--a disease of follicular helper T-cells?
Kempf W; Kazakov DV; Cipolat C; Kutzner H; Roncador G; Tomasini D
Am J Dermatopathol; 2012 Oct; 34(7):757-61. PubMed ID: 22722467
[TBL] [Abstract][Full Text] [Related]
48. Mycosis fungoides with spontaneously regressing CD30-positive tumorous lesions.
Woodrow SL; Basarab T; Russell Jones R
Clin Exp Dermatol; 1996 Sep; 21(5):370-3. PubMed ID: 9136160
[TBL] [Abstract][Full Text] [Related]
49. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
[TBL] [Abstract][Full Text] [Related]
50. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
Wong HK
G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
[TBL] [Abstract][Full Text] [Related]
51. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
Geskin LJ; Akilov OE; Kwon S; Schowalter M; Watkins S; Whiteside TL; Butterfield LH; Falo LD
Cancer Immunol Immunother; 2018 Mar; 67(3):423-434. PubMed ID: 29204699
[TBL] [Abstract][Full Text] [Related]
53. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
54. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
[TBL] [Abstract][Full Text] [Related]
55. Transition of Sézary syndrome into mycosis fungoides after complete clinical and molecular remission under extracorporeal photophoresis.
Assaf C; Hummel M; Zemlin M; Steinhoff M; Geilen CC; Stein H; Orfanos CE
J Clin Pathol; 2004 Dec; 57(12):1325-8. PubMed ID: 15563677
[TBL] [Abstract][Full Text] [Related]
56. Alemtuzumab in refractory Sézary syndrome.
Reifs CM; Salido-Vallejo R; Garnacho-Saucedo GM; Corte-Sánchez S; González-Menchen A; García-Nieto AV
An Bras Dermatol; 2016; 91(5):642-644. PubMed ID: 27828640
[TBL] [Abstract][Full Text] [Related]
57. Epstein-Barr virus-negative Hodgkin's lymphoma after mycosis fungoides: molecular evidence for distinct clonal origin.
Kremer M; Sandherr M; Geist B; Cabras AD; Höfler H; Fend F
Mod Pathol; 2001 Feb; 14(2):91-7. PubMed ID: 11235910
[TBL] [Abstract][Full Text] [Related]
58. Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature.
del Alcázar-Viladomiu E; Tuneu-Valls A; López-Pestaña A; Vidal-Manceñido MJ
Actas Dermosifiliogr; 2015 Sep; 106(7):e33-9. PubMed ID: 25960287
[TBL] [Abstract][Full Text] [Related]
59. Folliculotropic mycosis fungoides (stage IIA) progressing to Sézary syndrome: a case report.
Agar N; Whittaker SJ
Br J Dermatol; 2008 Nov; 159(5):1197-9. PubMed ID: 18764843
[TBL] [Abstract][Full Text] [Related]
60. A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin.
Corey K; Cook D; Bekker J; Mugnaini E; Lin JH
JAMA Dermatol; 2014 Feb; 150(2):210-2. PubMed ID: 24352253
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]